| Autor: |
Batra, Ullas, Nathany, Shrinidhi, Sharma, Mansi, Mattoo, Sakshi, Jose, Joslia T., Mehta, Anurag |
| Zdroj: |
JTO Clinical and Research Reports; March 2022, Vol. 3 Issue: 3 |
| Abstrakt: |
The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as ROS1for NSCLC. ROS1rearrangement has been observed in only 2% of cases of NSCLC and has been successfully targeted using various tyrosine kinase inhibitors including crizotinib. However, the on-target and off-target mechanisms of the resistance are still vague. Here, we report a case of a patient with ROS1rearranged NSCLC presenting primary resistance to crizotinib. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
